INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Mayo Clinic
Rochester, Estados UnidosPublicaciones en colaboración con investigadores/as de Mayo Clinic (152)
2023
-
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk
International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248
-
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Haematologica, Vol. 108, Núm. 8, pp. 2192-2204
-
Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis
CMAJ. Canadian Medical Association Journal, Vol. 66, Núm. 3, pp. E310-E320
-
Global disparities in patients with multiple myeloma: a rapid evidence assessment
Blood Cancer Journal, Vol. 13, Núm. 1
-
Identification of novel genetic loci for risk of multiple myeloma by functional annotation
Leukemia
-
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311
-
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
International Journal of Molecular Sciences, Vol. 24, Núm. 10
-
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients
Seminars in Hematology
-
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients
Seminars in Hematology
-
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials
Seminars in Hematology
-
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL
American Journal of Hematology, Vol. 98, Núm. 11, pp. 1699-1710
-
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 10, pp. 3010-3020
-
Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients
Blood, Vol. 141, Núm. 9, pp. 1036-1046
-
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222
2022
-
CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival
Cancers, Vol. 14, Núm. 2
-
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950
-
Guiding the global evolution of cytogenetic testing for hematologic malignancies
Blood, Vol. 139, Núm. 15, pp. 2273-2284
-
High frequency of central nervous system involvement in transformed Waldenstrom € macroglobulinemia
Blood Advances
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood, Vol. 140, Núm. 11, pp. 1200-1228
-
Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma
Current Medical Research and Opinion, Vol. 38, Núm. 10, pp. 1759-1767